NCT01975597

Brief Summary

This is a feasibility study to demonstrate the team's ability to collect bone marrow aspirates and biopsies for research purposes from women with metastatic breast cancer.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2013

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 3, 2013

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 4, 2013

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 19, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 19, 2014

Completed
Last Updated

September 1, 2023

Status Verified

August 1, 2023

Enrollment Period

1.3 years

First QC Date

September 3, 2013

Last Update Submit

August 30, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of patient that agree to undergo 2 biopsy's strictly for research purposes.

    At 3 months

Study Arms (1)

Bone marrow aspirates and biopsy

Procedure: Bone marrow aspirates and biopsy

Interventions

Bone marrow aspirates and biopsy

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are receiving care for metastatic breast cancer at University of Michigan Rogel Cancer Center will be recruited for this study to donate samples.

You may qualify if:

  • Patients with metastatic breast cancer (any site) age 21 or older
  • Patients willing and able to provide informed consent \& perform study procedures
  • Patients may enroll with recently (with 2 months) progressive tumor burden
  • Performance status of 0,1 or 2

You may not qualify if:

  • Patients unable or unwilling to provide informed consent and or perform study procedures
  • Patients with active, uncontrolled coagulopathy
  • Patients on treatment dose anticoagulation or an International Normalised Ratio of 2 or greater if on warfarin
  • Patients who are known to be pregnant are not eligible to participate in this study during the time of the pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Bone marrow, peripheral blood, tumor tissue

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Biopsy

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

CytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Catherine Van Poznak, MD

    University of Michigan Rogel Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 3, 2013

First Posted

November 4, 2013

Study Start

August 1, 2013

Primary Completion

November 19, 2014

Study Completion

November 19, 2014

Last Updated

September 1, 2023

Record last verified: 2023-08

Locations